Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PALB2 Antibodies:
anti-Mouse (Murine) PALB2 Antibodies:
anti-Rat (Rattus) PALB2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal PALB2 Primary Antibody for ICC, IF - ABIN253057
Brough, Bajrami, Vatcheva, Natrajan, Reis-Filho, Lord, Ashworth: APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. in The EMBO journal 2012
Show all 2 Pubmed References
Human Polyclonal PALB2 Primary Antibody for IHC, IP - ABIN253058
Martrat, Maxwell, Tominaga, Porta-de-la-Riva, Bonifaci, Gómez-Baldó, Bogliolo, Lázaro, Blanco, Brunet, Aguilar, Fernández-Rodríguez, Seal, Renwick, Rahman, Kühl, Neveling, Schindler, Ramírez et al.: Exploring the link between MORF4L1 and risk of breast cancer. ... in Breast cancer research : BCR 2011
Germline mutations in the PALB2 gene were observed at a frequency of approximately 1.5% in Polish breast and/or ovarian cancer patients
Prevalence of germline PALB2 mutations among women with epithelial ovarian cancer in Ontario
inherited pathogenic variants in PALB2 were associated with high risks of breast cancer
Findings establish L35P as the first pathogenic missense mutation in PALB2 and directly demonstrate the requirement of the PALB2-BRCA1 interaction for breast cancer suppression.
In this paper, we describe an extension to the BOADICEA model to incorporate the effects of intermediate risk variants for breast cancer, specifically loss of function mutations in the three genes for which the evidence for association is clearest and the risk estimates most precise: PALB2, CHEK2 (show CHEK2 Antibodies) and ATM (show ATM Antibodies)
Data show an increase of error-prone single-strand annealing (SSA (show TRIM21 Antibodies)) and microhomology-mediated end-joining (MMEJ) in the PALB2 (partner and localizer of BRCA2) c.1592delT mutation carriers.
Studies suggest that people with high risk of breast cancer and negative BRCA1/BRCA2 (show BRCA2 Antibodies) should be tested for PALB2 mutations.
PALB2 rare variants were associated with an increased risk of breast cancer.
our findings highlight a critical importance of PALB2 phosphorylation as a novel regulatory step in genome maintenance after genotoxic stress.
identification of a hidden nuclear export signal (NES (show NES Antibodies)) within the WD40 domain (show DCAF12L2 Antibodies) of PALB2 and found that the W1038X truncation leads to the exposure of this NES (show NES Antibodies) to CRM1 (show XPO1 Antibodies), an export protein
we describe a genetic approach to examine the functional significance of the interaction between BRCA2 (show BRCA2 Antibodies) and PALB2 by generating a knock-in mouse model of Brca2 (show BRCA2 Antibodies) carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 and Trp53 (show TP53 Antibodies) heterozygosity .
results underscore the in vivo importance of the PALB2-BRCA1 complex formation in DSB repair and male meiosis
Palb2 synergizes with Trp53 (show TP53 Antibodies) to suppress mammary tumor formation in a model of inherited breast cancer.
A key function for PALB2 is to interact with and to build up appropriate communication between BRCA1 (show BRCA1 Antibodies) and BRCA2 (show BRCA2 Antibodies).
This gene encodes a protein that may function in tumor suppression. This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2.
partner and localizer of BRCA2
, Fanconi N
, Fanconi anemia
, complementation group N
, partner and localizer of BRCA2-like